Jerome Deval

InstitutionAligos Therapeutics
AddressUnited States
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 5 Covid-19 publications, with a maximum of 2 publications in April 2021
    All Publications
    Bar chart showing 34 publications over 16 distinct years, with a maximum of 5 publications in 2016
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Vandyck K, Deval J. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Curr Opin Virol. 2021 08; 49:36-40. PMID: 34029993.
      Citations: 18     Fields:    Translation:HumansAnimals
    2. Scholle MD, Liu C, Deval J, Gurard-Levin ZA. Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry. SLAS Discov. 2021 07; 26(6):766-774. PMID: 33870746.
      Citations: 2     Fields:    Translation:HumansCells
    3. Vandyck K, Abdelnabi R, Gupta K, Jochmans D, Jekle A, Deval J, Misner D, Bardiot D, Foo CS, Liu C, Ren S, Beigelman L, Blatt LM, Boland S, Vangeel L, Dejonghe S, Chaltin P, Marchand A, Serebryany V, Stoycheva A, Chanda S, Symons JA, Raboisson P, Neyts J. ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model. Biochem Biophys Res Commun. 2021 05 28; 555:134-139. PMID: 33813272.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    4. Liu C, Boland S, Scholle MD, Bardiot D, Marchand A, Chaltin P, Blatt LM, Beigelman L, Symons JA, Raboisson P, Gurard-Levin ZA, Vandyck K, Deval J. Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development. Antiviral Res. 2021 03; 187:105020. PMID: 33515606.
      Citations: 5     Fields:    Translation:HumansCells
    5. Gurard-Levin ZA, Liu C, Jekle A, Jaisinghani R, Ren S, Vandyck K, Jochmans D, Leyssen P, Neyts J, Blatt LM, Beigelman L, Symons JA, Raboisson P, Scholle MD, Deval J. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry. Antiviral Res. 2020 10; 182:104924. PMID: 32896566.
      Citations: 7     Fields:    Translation:HumansCellsPHPublic Health